Back to Daily DR Market Summary

StreetAccount Summary - Asian Market Preview: Nikkei Futures (0.68%), Hang Seng Futures +0.72%, ASX SPI 200 +0.40%, S&P Futures +0.27%

Oct 11 ,2026

  • Synopsis:

    • Asian markets set for positive start to Monday trade. Futures signaling opening gains in Hong Kong and South Korea. Australia higher in early trade. Japan closed for public holiday. US contracts advancing following positive finish to the week. Australian bonds weakening after Treasury curve bear flattened Friday (no trading in Treasuries Monday due to US and Japan public holidays). FX markets steady. Crude swinging lower. Gold little changed while silver pushing higher. Bitcoin rebounding from near one-month low.

    • Saudi-Houthi conflict escalating after Houthis struck Riyadh airport again, killing multiple people, while President Trump signaled openness to joining campaign against Houthis. More of the same when it comes to Iran with IRGC vowing to continue striking vessels transiting Strait of Hormuz. US and Iran exchanging messages though remain apart on their demands. Refined fuels another focus after Trump announced diesel deal with Russia before claiming energy ceasefire between Ukraine and Russia.

    • Quiet Monday before economic activity picks up as IMF annual meetings get underway in Bangkok. Central bankers from Fed, ECB and BOE slated to remark. Big week of inflation data, including from US, China and India. China trade data follows stretch of strong growth in exports and imports underpinned by technology. RBA minutes to detail board discussions that informed September's rate hike. Australian employment comes after markets trimmed November rate hike odds following softer CPI. China credit data, Japan PPI and Singapore Q3 GDP also due out.

  • Pre-open Company News:

    • Morgan Stanley downgrades 542602.IN, 543261.IN

    • 002027.CH -- Focus Media Information Technology receives conditional anti-trust approval for Newchao Media acquisition

    • 540376.IN -- Avenue Supermarts reports Q2 standalone NPAT INR8.04B vs StreetAccount INR9.06B

    • 600062.CH -- China Resources Double-Crane Pharmaceutical receives NMPA marketing approval for API Vortioxetine Hydrobromide for depression in adult

    • 544632.IN -- Meesho Ltd. reports day 1 orders in mega blockbuster sale 2026 +~75% y/y

    • 9926.HK -- Akeso Inc doeses first patient in phase III perioperative study of cadonilimab (PD-1/CTLA-4) in colon cancer

    • 3692.HK -- Hansoh Pharmaceutical Group's marketing authoriztion application of Aumolertinib validated by EMA

    • 002714.CH -- Muyuan Foods reports September commercial pig sales of 6.4M pigs, +15.2% y/y

    • 543990.IN -- Signatureglobal (India) reports Q2 pre sales INR18.3B, (9%) vs year-ago INR20.2B

    • MIRM -- Mirum Pharmaceuticals to host investor call tomorrow, 12-Oct-26 at 08:30ET to share topline results from Phase 3 EXPAND study evaluating LIVMARLI

    • 2498.HK -- RoboSense Technology initiated overweight at Morgan Stanley

    • USITC launches Section 337 investigation into certain vertical power delivery systems for potential patent infringements (9-Oct)

    • 880.HK -- SJM Holdings upgraded to hold from underperform at CLSA

    • 068270.KS -- Celltrion reports preliminary Q3 revenue KRW1.5000T vs FactSet KRW1.457T [15 est, KRW1.399-1.537T]

  • On Deck:

    • Hong Kong:

      • Earnings:

        • CLP Holdings (2.HK)

    • India:

      • Earnings:

        • Gujarat State Fertilizers & Chemicals (500690.IN)

    • Taiwan:

      • Earnings:

        • Nanya Technology (2408.TT)

  • Market Data:

    • Gold (Dec 26): +$5.00 or +0.12% to $4221.30

    • WTI Crude (Nov 26): ($0.84) or (0.91%) to $91.01

    • $-¥: (0.11) or (0.07%) to 158.1780

    • $-KRW: +0.33 or +0.02% to 1340.8700

    • A$-$: +0.00 or +0.03% to 0.6987

    • $-INR: +0.26 or +0.27% to 96.7753

    • $-CNY: (0.00) or (0.02%) to 6.6914

This information and data is provided for general informational purposes only. The Bank of New York Mellon and our information suppliers do not warrant or guarantee the accuracy, timeliness or completeness of this information or data. We provide no advice nor recommendation or endorsement with respect to any company or securities. We do not undertake any obligation to update or amend this information or data. Nothing herein shall be deemed to constitute an offer to sell or a solicitation of an offer to buy securities.
Please refer to "Terms Of Use".

DEPOSITARY RECEIPTS:
NOT FDIC, STATE OR FEDERAL AGENCY INSURED
MAY LOSE VALUE
NO BANK, STATE OR FEDERAL AGENCY GUARANTEE